Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vical
To evaluate the safety and efficacy of 4 doses of VCL-HB01, a therapeutic HSV plasmid DNA vaccine formulated with Vaxfectin® in HSV-2-seropositive adults with a reported history of symptomatic genital herpes for at least one year.
Age
18–50
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
HSV-2 seropositive
A minimum of 1 year of reported history of genital herpes with recurrences.
You may not be if
History of receiving an investigational HSV vaccine
Chronic illness for which a subject's immune system is suspected to be impaired or altered, such as cancer, autoimmune conditions, or diabetes
